XML 99 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue and segmental reporting, Revenue recognised (Details) - GBP (£)
£ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disclosure of operating segments [line items]      
Revenue £ 30,114 £ 25,669 £ 23,654
United Kingdom [Member]      
Disclosure of operating segments [line items]      
Revenue 6,356 5,753 6,079
United States [Member]      
Disclosure of operating segments [line items]      
Revenue 23,758 19,916 17,575
GlaxoSmithKline [Member]      
Disclosure of operating segments [line items]      
Revenue 6,356 5,753 6,079
Eli Lilly [Member]      
Disclosure of operating segments [line items]      
Revenue 3,522 819 8,561
Genentech [Member]      
Disclosure of operating segments [line items]      
Revenue 20,236 19,097 1,461
Med Immune [Member]      
Disclosure of operating segments [line items]      
Revenue £ 0 £ 0 £ 7,553